CBAY | CymaBay Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	32.48 - 32.50
52 Week Range	7.26 - 32.50
Beta	0.21
Implied Volatility	31.69%
IV Rank	0.05%
Day's Volume	8,354,629
Average Volume	3,944,615
Shares Outstanding	114,785,000
Market Cap	3,728,216,800
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-02-03

Valuation
Profitability
Growth
Health
P/E Ratio	-32.81
Forward P/E Ratio	-11.57
EPS	-0.99
1YR Price Target	12.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	101
Country	USA
Website	CBAY

At CymaBay, we are committed to improving the lives of patients with liver and other chronic diseases by developing and providing access to innovative therapies. Our evidence-based decision making and commitment to the highest quality standards reflect our relentless dedication to the patients, families and communities we serve.

CBAY's peers: ARTLW

*Chart delayed

Analyzing fundamentals for CBAY we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see CBAY Fundamentals page.

Watching at CBAY technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CBAY Technicals page.